Cervical Local Immune Response for High-Risk Human Papillomavirus Infection: Involvement With Cervical Mucus SLPI Proteins


Creative Commons License

Sahin E. , MADENDAĞ Y. , SAHIN M. E. , MADENDAG I. C. , AÇMAZ G. , Karakukcu C. , ...More

CANCER CONTROL, vol.25, no.1, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.1177/1073274818798598
  • Title of Journal : CANCER CONTROL
  • Keywords: cervical immune response, human papillomavirus, high-risk HPV, LGSIL, HGSIL, secretory leukocyte protease inhibitor (SLPI), LEUKOCYTE PROTEASE INHIBITOR, CANCER, EXPRESSION, INDUCTION

Abstract

Purpose: To evaluate cervical mucus secretory leukocyte protease inhibitor (SLPI) concentrations in patients with high-risk human papillomavirus (hrHPV) 16 or 18 positive and low-grade squamous intraepithelial lesions (LGSIL) or high-grade squamous intraepithelial lesions (HGSIL).